Alex F. Herrera, MD, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed or refractory Hodgkin lymphoma.
Alex F. Herrera, MD, a hematologist/oncologist at the City of Hope Cancer Center, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed/ refractory (R/R) Hodgkin lymphoma (HL).
There are many treatment options available for patients living with R/R HL. Drugs like rituximab (Rituxan), nivolumab (Opdivo), and pembrolizumab (Keytruda) have greatly improved survival rates for patients. But, according to Herrera, very few options remain for patients whose tumors are resistant to these drugs.
For patients who cannot be cured through these conventional means, treatment options are desperately needed. Camidanlumab tesirine works by binding CD25 and delivers chemotherapy to the cancer cell.